Tony Berberabe, MPH | Authors

October 12, 2021

Caron A. Jacobson, MD, MMSC, highlights data supporting the use of CAR T-cell therapy in patients with indolent lymphoma.

September 24, 2021

Patients with high-risk polycythemia vera had a worse survival probability at 4 years compared to patients with low-risk disease.

September 16, 2021

Further results from the KEYNOTE-426 trial continue to support the combination of pembrolizumab plus axitinib in patients with clear cell renal cell carcinoma.

September 09, 2021

The introduction of targeted therapies and immunotherapeutics may work to improve survival for patients with T-cell acute lymphoblastic leukemia.

July 09, 2021

Results from the phase 3 KEYNOTE-811 study indicated that pembrolizumab and trastuzumab plus chemotherapy yielded robust, long-lasting responses in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer.

June 15, 2021

Real-world evidence evaluating the efficacy of rituximab maintenance following frontline BR or R-CHOP supports its use in mantle cell lymphoma.

June 08, 2021

Data from the MonumentTAL-1 trial detailed the benefits with the recommended phase II dose of talquetamab to treat patients with relapsed/refractory multiple myeloma.

June 06, 2021

About 40% of patients who progressed on placebo following resection of melanoma experienced an objective response with crossover to pembrolizumab in the phase 3 EORTC 1325/KEYNOTE-054 trial.

June 04, 2021

The phase 1 dose-finding CTNO1552101 trial of TN0155 in adults with advanced solid tumors reported initial results at the 2021 ASCO Annual Meeting.

March 25, 2021

In addition to promising effects on tumor progression risk, apatinib added to doxorubicin for ovarian cancer in certain settings increased overall response rate versus single-agent doxorubicin.